Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 2012-004954-27 | EudraCT Number |
Not provided
Not provided
Not provided
Unable to recruit sufficient participants
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Oxford Fertility Unit | OTHER |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Endometriosis is a hormone dependent disease of women, in which endometrial tissue (the cells which line the uterus or womb) are found outside the uterus (womb). Some women with endometriosis may be infertile. However, treatments for infertility such as in vitro fertilization (IVF) or IVF with intracytoplasmic sperm injection (IVF-ICSI) appear to be less successful, i.e. the pregnancy rates are lower, for women with endometriosis than for women who may be infertile for other reasons.
Since endometriosis is hormone dependent, it has been suggested that suppressing the activity of hormones produced by the ovaries (which affect endometrial growth) may inactivate endometriosis and so increase the chances of pregnancy. Recently it has been proposed that taking the oral contraceptive pill (OCP) for 6 to 8 weeks before IVF or IVF-ICSI treatment could be used for this purpose.
For our study, which is a randomised controlled trial, women with endometriosis meeting the study criteria planning to undergo IVF or IVF-ICSI at the Oxford Fertility Unit will be recruited. Study participants will be randomised into 2 arms: experimental group and control group. The experimental group will be instructed to complete an 8 week course of OCP before beginning standard IVF treatment. The control group do not take any study medication before beginning standard IVF treatment. The IVF or IVF-ICSI treatment for both groups is not altered by participation in the study.
The aim of the study will be to determine if pretreatment with OCP improves IVF or IVF-ICSI success rates, such as live birth and pregnancy rates, in patients who suffer from endometriosis. The study is funded by the Oxford Fertility Unit.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Group 1 OCP | Experimental | Combined oral contraceptive pill (OCP) (Microgynon 30) containing Levonorgestrel/Ethinylestradiol 150/30mcg. Taken orally on a continuous regime for 8 weeks, once a day. |
|
| Group 2 Control | No Intervention | Control Group - no intervention |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Combined Oral Contraceptive Pill (Microgynon 30) | Drug | Pre-IVF treatment for 8 weeks |
|
| Measure | Description | Time Frame |
|---|---|---|
| Live birth rate | The birth of a live child after 24 gestational weeks | up to 40 weeks following embryo transfer date |
| Measure | Description | Time Frame |
|---|---|---|
| IVF Cycle outcomes | Cancelled cycles, failed cycles - negative pregnancy test, biochemical pregnancy, clinical pregnancy, miscarriage, stillbirth | up to 40 weeks following embryo transfer date |
| Treatment responses per cycle |
Not provided
Inclusion Criteria:
Participant is willing and able to give informed consent for participation in the study.
Exclusion Criteria:
The participant does not understand the English language, or has special communication needs. This is because it is impractical to provide, for this small scale study, information sheets and consent forms in other languages except English.
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Tim Child | University of Oxford | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| NDOG, University of Oxford | Oxford | OX4 2HW | United Kingdom |
Not provided
| ID | Term |
|---|---|
| D003277 | Contraceptives, Oral, Combined |
| ID | Term |
|---|---|
| D004338 | Drug Combinations |
| D004364 | Pharmaceutical Preparations |
| D003276 | Contraceptives, Oral |
| D003271 | Contraceptive Agents, Female |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
No. of follicles aspirated, No. of oocytes retrieved, No. of cleavage embryos obtained, Total dose and duration of Gonadotrophins
| up to one week after egg collection |
| Number of cases of Ovarian Hyperstimulation Syndrome | Up to 4 weeks after final embryo transfer |
| Multiple pregnancy rate | Up to 6 weeks after final embryo transfer |
| Number of ectopic pregnancies | up to 6 weeks after embryo transfer |
| D003270 | Contraceptive Agents |
| D012102 | Reproductive Control Agents |
| D045505 | Physiological Effects of Drugs |
| D020228 | Pharmacologic Actions |
| D020164 | Chemical Actions and Uses |
| D045506 | Therapeutic Uses |